Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (8): 471-475.
Previous Articles Next Articles
GAO Jing, YANG Yue
Received:
2015-09-02
Revised:
2015-09-02
Online:
2015-08-08
Published:
2015-09-02
CLC Number:
GAO Jing, YANG Yue. Improvement and Discussion of Review Model for New Drugs in America[J]. Chinese Journal of Pharmacovigilance, 2015, 12(8): 471-475.
[1] Cantor D J. Prescription Drug User Fee Act of 1992: Effects On Bringing New Drugs To Market[C]. Congressional Research Service, Library of Congress, 1997:97-838E. [2] John K. Jenkins. CDER New Drug Review: 2014 Update[EB/OL]. (2014-12-11) [2015-06-05]. http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacOf/CDER/UCM426549.pdf. [3] FDA.Assessment of the Program for Enhanced Review Transparency and Communication for New Molecular Entity New Drug Applications and Original Biologics License Applications in Prescri-ption Drug User Fee Act V; Request for Comments[J]. Federal Register, 2012, 77(130): 40072-40073. [4] Judit Milstein. 21st Century Review[EB/OL].(2013-07-19)[2015-06-07].http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM361324.pdf. [5] Eastern Research Group, Inc. Assessment of the Program for Enhanced Review Transparency and Communication for NMENDAs and Original BLAs in PDUFA V Interim Report: Fiscal Years 2013-2014[EB/OL].(2015-03-27)[2015-06-15].http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM436448.pdf. [6] 王建英. 美国药品申报与法规管理[M].北京:中国医药科技出版 2005:29,147. [7] CDER. WORLD OF CDER ADVISORY COMMITTEE PROCESS MODULE[EB/OL].[2015-07-04].http://www.accessdata.fda.gov/scripts/cderworld/index.cfm?action=advisorycommitteeprocess:main&unit=1&lesson=1&topic=5&page=1. [8] 张象麟,刘璐,叶祖光. 简介美国药品专家咨询委员会及我国药品专家审评委员会[J].中国新药杂志,2013,12(10):789-791. [9] FDA. Membership Types[EB/OL].(2015-05-20)[2015-07-04].http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/CommitteeMembership/MembershipTypes/default.htm. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||